Kandel, E. R., Koester, J. D., Mack, S. H. & Siegelbaum, S. A. Principles of Neural Science 6th edn (McGraw Hill Professional, 2021).
Ng, J., Papandreou, A., Heales, S. J. & Kurian, M. A. Monoamine neurotransmitter disorders—clinical advances and future perspectives. Nat. Rev. Neurol. 11, 567–584 (2015).
Google Scholar
Eiden, L. E. & Weihe, E. VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse. Ann. N.Y. Acad. Sci. 1216, 86–98 (2011).
Google Scholar
Schuldiner, S., Shirvan, A. & Linial, M. Vesicular neurotransmitter transporters: from bacteria to humans. Physiol. Rev. 75, 369–392 (1995).
Google Scholar
Yaffe, D., Forrest, L. R. & Schuldiner, S. The ins and outs of vesicular monoamine transporters. J. Gen. Physiol. 150, 671–682 (2018).
Google Scholar
Wimalasena, K. Vesicular monoamine transporters: structure–function, pharmacology, and medicinal chemistry. Med. Res. Rev. 31, 483–519 (2011).
Google Scholar
Davis, M. C., Miller, B. J., Kalsi, J. K., Birkner, T. & Mathis, M. V. Efficient trial design—FDA approval of valbenazine for tardive dyskinesia. N. Engl. J. Med. 376, 2503–2506 (2017).
Google Scholar
Huntington Study Group. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. J. Am. Med. Assoc. 316, 40–50 (2016).
Google Scholar
Siddiqui, M., Bhatt, H., Judd, E. K., Oparil, S. & Calhoun, D. A. Reserpine substantially lowers blood pressure in patients with refractory hypertension: a proof-of-concept study. Am. J. Hypertens. 33, 741–747 (2020).
Google Scholar
Takahashi, N. et al. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc. Natl Acad. Sci. USA 94, 9938–9943 (1997).
Google Scholar
Wang, Y.-M. et al. Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 19, 1285–1296 (1997).
Google Scholar
Fon, E. A. et al. Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron 19, 1271–1283 (1997).
Google Scholar
Saida, K. et al. Brain monoamine vesicular transport disease caused by homozygous SLC18A2 variants: a study in 42 affected individuals. Genet. Med. 25, 90–102 (2023).
Google Scholar
Drew, D. & Boudker, O. Shared molecular mechanisms of membrane transporters. Annu. Rev. Biochem. 85, 543–572 (2016).
Google Scholar
Drew, D., North, R. A., Nagarathinam, K. & Tanabe, M. Structures and general transport mechanisms by the major facilitator superfamily (MFS). Chem. Rev. 121, 5289–5335 (2021).
Google Scholar
Yan, N. Structural biology of the major facilitator superfamily transporters. Annu. Rev. Biophys. 44, 257–283 (2015).
Google Scholar
Parsons, S. M. Transport mechanisms in acetylcholine and monoamine storage. FASEB J. 14, 2423–2434 (2000).
Google Scholar
Erickson, J. D., Eiden, L. E. & Hoffman, B. J. Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc. Natl Acad. Sci. USA 89, 10993–10997 (1992).
Google Scholar
Liu, Y. et al. A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. Cell 70, 539–551 (1992).
Google Scholar
Weihe, E., Schäfer, M. K., Erickson, J. D. & Eiden, L. E. Localization of vesicular monoamine transporter isoforms (VMAT1 and VMAT2) to endocrine cells and neurons in rat. J. Mol. Neurosci. 5, 149–164 (1994).
Google Scholar
Peter, D. et al. Differential expression of two vesicular monoamine transporters. J. Neurosci. 15, 6179–6188 (1995).
Google Scholar
Erickson, J. D. & Eiden, L. E. Functional identification and molecular cloning of a human brain vesicle monoamine transporter. J. Neurochem. 61, 2314–2317 (1993).
Google Scholar
Nikkhah, A. A brief review on the role of vesicular monoamine transporter2 inhibitors in hyperkinetic movement disorders. Iran. J. Child Neurol. 15, 29–33 (2021).
Google Scholar
Chen, J. J., Ondo, W. G., Dashtipour, K. & Swope, D. M. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin. Ther. 34, 1487–1504 (2012).
Google Scholar
Harriott, N. D., Williams, J. P., Smith, E. B., Bozigian, H. P. & Grigoriadis, D. E. VMAT2 inhibitors and the path to Ingrezza (valbenazine). Prog. Med. Chem. 57, 87–111 (2018).
Google Scholar
Weir, M. R. Reserpine: a new consideration of an old drug for refractory hypertension. Am. J. Hypertens. 33, 708–710 (2020).
Google Scholar
Fraser, H. S. Reserpine: a tragic victim of myths, marketing, and fashionable prescribing. Clin. Pharmacol. Ther. 60, 368–373 (1996).
Google Scholar
Lobay, D. Rauwolfia in the treatment of hypertension. Integr. Med. 14, 40–46 (2015).
Scherman, D. & Henry, J. P. Reserpine binding to bovine chromaffin granule membranes. Characterization and comparison with dihydrotetrabenazine binding. Mol. Pharmacol. 25, 113–122 (1984).
Google Scholar
Darchen, F., Scherman, D. & Henry, J. P. Reserpine binding to chromaffin granules suggests the existence of two conformations of the monoamine transporter. Biochemistry 28, 1692–1697 (1989).
Google Scholar
Schuldiner, S., Liu, Y. & Edwards, R. H. Reserpine binding to a vesicular amine transporter expressed in Chinese hamster ovary fibroblasts. J. Biol. Chem. 268, 29–34 (1993).
Google Scholar
Liu, Y. & Edwards, R. H. The role of vesicular transport proteins in synaptic transmission and neural degeneration. Annu. Rev. Neurosci. 20, 125–156 (1997).
Google Scholar
Peter, D., Jimenez, J., Liu, Y., Kim, J. & Edwards, R. H. The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors. J. Biol. Chem. 269, 7231–7237 (1994).
Google Scholar
Støve, S. I., Skjevik, Å. A., Teigen, K. & Martinez, A. Inhibition of VMAT2 by β2-adrenergic agonists, antagonists, and the atypical antipsychotic ziprasidone. Commun. Biol. 5, 1283 (2022).
Google Scholar
Ugolev, Y., Segal, T., Yaffe, D., Gros, Y. & Schuldiner, S. Identification of conformationally sensitive residues essential for inhibition of vesicular monoamine transport by the noncompetitive inhibitor tetrabenazine. J. Biol. Chem. 288, 32160–32171 (2013).
Google Scholar
Kanner, B. I., Fishkes, H., Maron, R., Sharon, I. & Schuldiner, S. Reserpine as a competitive and reversible inhibitor of the catecholamine transporter of bovine chromaffin granules. FEBS Lett. 100, 175–178 (1979).
Google Scholar
Erickson, J. D., Schafer, M. K., Bonner, T. I., Eiden, L. E. & Weihe, E. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc. Natl Acad. Sci. USA 93, 5166–5171 (1996).
Google Scholar
Yaffe, D., Vergara-Jaque, A., Forrest, L. R. & Schuldiner, S. Emulating proton-induced conformational changes in the vesicular monoamine transporter VMAT2 by mutagenesis. Proc. Natl Acad. Sci. USA 113, E7390–E7398 (2016).
Google Scholar
Steiner-Mordoch, S., Shirvan, A. & Schuldiner, S. Modification of the pH profile and tetrabenazine sensitivity of rat VMAT1 by replacement of aspartate 404 with glutamate. J. Biol. Chem. 271, 13048–13054 (1996).
Google Scholar
Merickel, A., Kaback, H. R. & Edwards, R. H. Charged residues in transmembrane domains II and XI of a vesicular monoamine transporter form a charge pair that promotes high affinity substrate recognition. J. Biol. Chem. 272, 5403–5408 (1997).
Google Scholar
Merickel, A., Rosandich, P., Peter, D. & Edwards, R. H. Identification of residues involved in substrate recognition by a vesicular monoamine transporter. J. Biol. Chem. 270, 25798–25804 (1995).
Google Scholar
Yaffe, D., Radestock, S., Shuster, Y., Forrest, L. R. & Schuldiner, S. Identification of molecular hinge points mediating alternating access in the vesicular monoamine transporter VMAT2. Proc. Natl Acad. Sci. USA 110, E1332–E1341 (2013).
Google Scholar
Yaffe, D. et al. Functionally important carboxyls in a bacterial homologue of the vesicular monoamine transporter (VMAT). J. Biol. Chem. 289, 34229–34240 (2014).
Google Scholar
Chen, H. et al. Structural and functional insights into Spns2-mediated transport of sphingosine-1-phosphate. Cell 186, 2644–2655 (2023).
Google Scholar
Binz, H. K. et al. High-affinity binders selected from designed ankyrin repeat protein libraries. Nat. Biotechnol. 22, 575–582 (2004).
Google Scholar
Hu, G. et al. New fluorescent substrate enables quantitative and high-throughput examination of vesicular monoamine transporter 2 (VMAT2). ACS Chem. Biol. 8, 1947–1954 (2013).
Google Scholar
Weaver, J. A. & Deupree, J. D. Conditions required for reserpine binding to the catecholamine transporter on chromaffin granule ghosts. Eur. J. Pharmacol. 80, 437–438 (1982).
Google Scholar
Stern-Bach, Y., Greenberg-Ofrath, N., Flechner, I. & Schuldiner, S. Identification and purification of a functional amine transporter from bovine chromaffin granules. J. Biol. Chem. 265, 3961–3966 (1990).
Google Scholar
Rudnick, G., Steiner-Mordoch, S. S., Fishkes, H., Stern-Bach, Y. & Schuldiner, S. Energetics of reserpine binding and occlusion by the chromaffin granule biogenic amine transporter. Biochemistry 29, 603–608 (1990).
Google Scholar
Goehring, A. et al. Screening and large-scale expression of membrane proteins in mammalian cells for structural studies. Nat. Protoc. 9, 2574–2585 (2014).
Google Scholar
Kawate, T. & Gouaux, E. Fluorescence-detection size-exclusion chromatography for precrystallization screening of integral membrane proteins. Structure 14, 673–681 (2006).
Google Scholar
Bolte, S. & Cordelières, F. P. A guided tour into subcellular colocalization analysis in light microscopy. J. Microsc. 224, 213–232 (2006).
Google Scholar
Rana, M. S., Wang, X. & Banerjee, A. An improved strategy for fluorescent tagging of membrane proteins for overexpression and purification in mammalian cells. Biochemistry 57, 6741–6751 (2018).
Google Scholar
Zheng, S. Q. et al. MotionCor2—anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331–332 (2017).
Google Scholar
Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 (2017).
Google Scholar
Bepler, T. et al. Positive-unlabeled convolutional neural networks for particle picking in cryo-electron micrographs. Nat. Methods 16, 1153–1160 (2019).
Google Scholar
Punjani, A., Zhang, H. & Fleet, D. J. Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction. Nat. Methods 17, 1214–1221 (2020).
Google Scholar
Zivanov, J. et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. eLife 7, e42166 (2018).
Google Scholar
Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583–589 (2021).
Google Scholar
Pettersen, E. F. et al. UCSF Chimera—a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612 (2004).
Google Scholar
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486–501 (2010).
Google Scholar
Croll, T. I. ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. Acta Crystallogr. D 74, 519–530 (2018).
Google Scholar
Afonine, P. V. et al. Real-space refinement in PHENIX for cryo-EM and crystallography. Acta Crystallogr. D 74, 531–544 (2018).
Google Scholar
Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D 66, 12–21 (2010).
Google Scholar
Goddard, T. D. et al. UCSF ChimeraX: meeting modern challenges in visualization and analysis. Protein Sci. 27, 14–25 (2018).
Google Scholar
Black, C. A. et al. Assessing vesicular monoamine transport and toxicity using fluorescent false neurotransmitters. Chem. Res. Toxicol. 34, 1256–1264 (2021).
Google Scholar